Compass Therapeutics Receives 'Moderate Buy' Rating from Analysts

Biotechnology company's stock gets consensus recommendation from 14 rating firms

Feb. 26, 2026 at 10:24am

Got story updates? Submit your updates here. ›

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have received an average 'Moderate Buy' rating from 14 equity research analysts covering the company. The analysts have a 1-year average price target of $13.36 on the stock.

Why it matters

Compass Therapeutics is a clinical-stage biotech company focused on developing novel immuno-oncology therapies. The 'Moderate Buy' consensus rating from analysts suggests they are generally bullish on the company's prospects, which could signal confidence in its pipeline of cancer treatment candidates.

The details

The 14 analysts covering Compass Therapeutics have provided the following ratings: 1 'Sell', 12 'Buy', and 1 'Strong Buy'. Several analysts have recently weighed in, with Canaccord Genuity Group setting a $13 price target, Weiss Ratings issuing a 'Sell (d-)' rating, and Raymond James Financial reiterating an 'Outperform' rating with a $9 price target. Citigroup also assumed coverage with an 'Outperform' rating.

  • Compass Therapeutics stock opened at $5.89 on Friday, February 26, 2026.
  • The company's 52-week trading range is $1.33 to $6.88.

The players

Compass Therapeutics, Inc.

A clinical-stage biotechnology company dedicated to developing novel immuno-oncology therapies. The company is headquartered in Cambridge, Massachusetts.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

The 'Moderate Buy' consensus rating from analysts suggests they see promise in Compass Therapeutics' pipeline of cancer immunotherapy candidates, though there are some differing views on the stock's valuation and prospects.